Home Cart Sign in  
Chemical Structure| 486-21-5 Chemical Structure| 486-21-5

Structure of Isofraxidin
CAS No.: 486-21-5

Chemical Structure| 486-21-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Isofraxidin, a natural product isolated and purified from the herbs of Sarcandra glabra (Thunb.) Nakai, possesses significant analgesic and anti-inflammatory activities that may be mediated through the regulation of pro-inflammatory cytokines, TNF-α and the phosphorylation of p38 and ERK1/2.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Isofraxidin

CAS No. :486-21-5
Formula : C11H10O5
M.W : 222.19
SMILES Code : O=C1C=CC2=CC(OC)=C(O)C(OC)=C2O1
MDL No. :MFCD00221757
InChI Key :HOEVRHHMDJKUMZ-UHFFFAOYSA-N
Pubchem ID :5318565

Safety of Isofraxidin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Isofraxidin

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW 264.7 macrophages 0.03, 0.06, and 0.06 mmol 24 hours To investigate the effect of C + R + I on LPS-induced inflammatory factors and oxidative stress in RAW 264.7 macrophages. Results showed that C + R + I significantly suppressed the levels of nitric oxide (NO), pro-inflammatory cytokines, and inhibited iNOS and COX-2 expression. Front Pharmacol. 2021 Jan 11;11:580064
Bone marrow-derived macrophages (BMMs) 12.5 µM 8 hours To evaluate the effect of isofraxidin on RANKL-induced NFATc1 transcriptional activity, results showed that isofraxidin inhibited NFATc1 activation. Cell Transplant. 2021 Jan-Dec;30:963689721990321
Bone marrow-derived macrophages (BMMs) 6.25 and 12.5 µM 4 days To evaluate the effect of isofraxidin on RANKL-induced osteoclast formation in BMMs, results showed that isofraxidin inhibited TRAP activity and osteoclast formation. Cell Transplant. 2021 Jan-Dec;30:963689721990321
Bone marrow-derived macrophages (BMMs) 6.25 and 12.5 µM 24 hours To evaluate the effect of isofraxidin on BMMs cell viability, results showed that 6.25 and 12.5 µM concentrations did not affect cell viability. Cell Transplant. 2021 Jan-Dec;30:963689721990321

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Chronic unpredictable mild stress (CUMS)-induced depressive model Oral gavage 3, 10, 30 mg/kg Once daily for 4 weeks Isofraxidin significantly reversed CUMS-induced decrease in body weight gain, sucrose preference, locomotor activity, and increased immobility time in the forced swimming test (FST) and tail suspension test (TST). Additionally, isofraxidin decreased serum levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH), and hypothalamic corticotropin-releasing hormone (CRH), suppressed the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in the hippocampus, and inhibited CUMS-induced activation of nuclear factor kappa B (NF-κB) and NOD-like receptor protein 3 (NLRP3) inflammasomes in the hippocampus. Brain Sci. 2022 Oct 11;12(10):1376
BALB/c mice LPS-induced acute lung injury model Intraperitoneal injection High dose (50, 20, and 20 mg/kg), middle dose (25, 10, and 10 mg/kg), low dose (12.5, 5, and 5 mg/kg) Once daily for three days To investigate the protective effect of C + R + I on LPS-induced acute lung injury in mice. Results showed that C + R + I significantly alleviated lung histopathological damage, reduced inflammatory cell infiltration, and inhibited the activation of the MAPK-NF-κB signaling pathway. Front Pharmacol. 2021 Jan 11;11:580064
Swiss albino mice LPS-induced cytokine release syndrome Intraperitoneal 15 mg/kg Once daily for 3 days Isofraxidin alone or in combination with methylprednisolone ameliorates LPS-induced inflammatory and oxidative stress damage in mice, reduces inflammatory and oxidative stress markers, and prevents LPS-induced liver and lung tissue damage. Biomedicines. 2025 Mar 7;13(3):653

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.50mL

0.90mL

0.45mL

22.50mL

4.50mL

2.25mL

45.01mL

9.00mL

4.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories